Understanding Drug-Human Interactions
ImmunoMind uses AI and multi-omics to predict the efficacy of immunotherapies and stratify patients.
Moonshot startup from UC Berkeley SkyDeck
From the team behind Immunarch – the gold standard for immunomics data analysis, trusted by:
Pfizer · Novartis · UCSF · Stanford · MIT · MD Anderson Cancer Center ·
The Johns Hopkins University School of Medicine
and the global community of 60,000 medical scientists and researchers worldwide
  • Immunotherapy efficacy prediction by deciphering the drug-human interactions
  • Patient stratification and monitoring using identified multi-omics biomarkers
  • Leverage single-cell and bulk multi-omics technologies for precision immunotherapy development
Early assessment of CAR-T cell population essential characteristics helps improve the probability of success in later drug development stages. ImmunoMind's platform automatically evaluates CAR-T cells' activation, proliferation, cytotoxicity, senescence, and exhaustion. The platform simultaneously compares the characteristics of several CAR-T products and helps companies choose the best candidate.
T cell exhaustion is a dysfunctional state of T-cells arising from excessive antigen stimulation. It is considered to be one of the critical factors at all stages of CAR-T development and manufacturing. ImmunoMind's technologies precisely evaluate CAR-T cell exhaustion and help in developing effective therapies.
Heterogeneity subpopulations and CD4+/CD8+ ratio are vital attributes of CAR-T product that should be analyzed for the development of effective drugs. By using single-cell technologies, it is now possible to dive into the internal context of CAR-T products, while delineating cell subtypes and cell diversity.
Efficacy is diminished due to the predominance of more differentiated cells in the final CAR-T product. Identification of various differentiated subpopulations results in the ability to optimize the CAR-T manufacturing process. The actionable insights provided by ImmunoMind assist when selecting the most effective composition of a CAR-T product and allow modification of the manufacturing process.
Why partner with us?
Biotech Startups De-risk
De-risk immunotherapy on the crucial discovery steps by focusing on the most efficient immunotherapy candidates.
Immunotherapy Biopharma Better Efficacy
Focus on immunotherapy candidates that work and stratify patients for successful clinical trials.
Research Groups – Fuel Discovery
Study immune cell biology and discover new targets and biomarkers for immunotherapies with the AI and bioinformatics capabilities of ImmunoMind.
Made on